Sengenics Company

Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics.

The key application of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events. Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests.

Investors

Founded Date: 1996-01-01
Industry: Quantum Biology
Employee Number: 51-100
Last Funding Date: 2019-11-26
Funding Status: private
Headquarters: Singapore,Central Region,Singapore,Asia
Super Industry: Quantum Science Applications
Funding Stage: M&A
Founders: Arif Anwar
Phone Number: +44 (0) 1223 92 6588
Register and Claim Ownership